They have a proven team at CHM ready to lead the way, with a nice cash balance in hand. I am very excited for the future, having just taken more shares in the recent placement. I know it is still risky at these levels and nothing is for certain, but the risk to reward ratio here is immense.
3 major programs below all that have the ability to change the world forever if successful:
CHM CDH17 (Program 1: CAR T)CAR-T for gastrointestinal cancers, including bowel cancer – LEAD PROGRAMDose Level 1 completed; four patients dosedExcellent safety and early efficacy signals; no off- target effects. Stable disease in rapidly progressing patient observed at Dose level 1.Recruitment rate is exceptional with ten patients on waitlist. Ready to proceed to dose level 2
CHM CLTX (Program 2: CAR T)CAR-T for brain cancerOngoing Phase 1B clinical trial in recurrent glioblastoma
CHM CORE-NK (Program 3: Natural Killer Cells)Positive Phase 1A clinical trial in colorectal cancer (CRC) and acute myeloid leukemia (AML)Two ongoing Phase 1B trials in AMLIn ADVENT-AML, 2 of 3 frontline patients achieved CRi (remission); 1 patient achieved Stable DiseaseFirst ever frontline AML trial globally to incorporate NK cell therapy
CHM Price at posting:
0.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)